Clinical-stage partner ExpreS2ionBiotechnologies is a clinical-stage DK biotech focused on vaccines and immunotherapies, offering a platform (ExpreS2) for fast development and production of complex proteins, which presents opportunities for collaboration on new vaccine and biologics programs.

Platform advantages Their proprietary ExpreS2 expression system and cVLP (capsid virus-like particle) platform enable long-term efficacy, safety, stability, and cost advantages, creating potential sell points for partners seeking scalable, cost-efficient vaccine/therapeutic manufacturing solutions.

Strategic partnerships Co-development and collaboration history with academic partners and industry players, plus a 34%-owned affiliate AdaptVac, signals a readiness for joint ventures and licensing deals to accelerate pipeline programs such as Nipah and malaria vaccines.

Clinical pipeline Active programs include ES2B-C001 breast cancer vaccine and Nipah vaccine preclinical work, alongside malaria vaccine projects and influenza candidates, offering multiple entry points for CROs, contract manufacturers, and strategic investors interested in immunotherapy and vaccinology.

Market presence Regular participation in major life sciences conferences (Sachs Associates CEO Forum, BIO-Europe) and ongoing GLP safety studies for ES2B-C001 demonstrate active business development and potential for advisory, partnering, and distribution opportunities with global biotech partners.